Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Dartmouth-Hitchcock Medical Center
Study ID
NCT00039468
Phase
PHASE2
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Thalidomide may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with irinotecan may kill any tumor cells remaining after radiation therapy. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide with irinotecan in treating patients who have glioblastoma multiforme that has been treated with radiation therapy.

Key Dates

Start date
Mar 31, 2002
Status verified
Oct 2011
Primary completion
Sep 30, 2007
Completion
Feb 29, 2008

Study Design

Enrollment
26 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Response [ Time Frame: 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical CenterLebanonNew Hampshire03756-0002-
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State UniversityColumbusOhio43210-1240-

Find similar trials in Lebanon, NH

By research site
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center· Lebanon, NHArthur G. James Cancer Hospital and Solove Research Institute at Ohio State University· Columbus, OH

Related Studies